Denosumab prevents periprosthetic bone mineral density loss in the tibial metaphysis in total knee arthroplasty

Denosumab prevents periprosthetic bone mineral density loss in the tibial metaphysis in total knee arthroplasty - The effect of denosumab in periprosthetic bone mineral density

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000035653

Enrollment

Registered

2019-01-25

Start date

2014-12-11

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary osteoarthritis of knee

Interventions

Patients in the intervention group received 0.5 ug vitamin D3 (Alfacalcidol) daily and 60 mg denosumab every 6 months from the day after total knee arthroplasty for 12 months. Patients in the control

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: We include only patients with osteoporosis and primary osteoarthritis of the knee.

Exclusion criteria

Exclusion criteria: We exclude patients who are undergoing revision surgery, and those who had previously taken anti-osteoporotic drugs or other medications known to influence bone mineral metabolism.

Design outcomes

Primary

Measure	Time frame
We measure periprosthetic bone mineral density using dual energy X-ray absorptiometry after total knee arthroplasty for 12 months.	—

Countries

Japan

Contacts

Public ContactYasutaka Murahashi

Sapporo Medical Univ. School of Medicine Department of Orthopaedic Surgery

yayayaya1126@yahoo.co.jp01161112111(33330)

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026